Stevanato Group S.p.A (STVN) Cash from Investing Activities (2020 - 2026)
Stevanato Group S.p.A (STVN) reported Cash from Investing Activities of -$82.4 million for Q1 2026, down 10.81% year-over-year from -$92.4 million in Q1 2025, and up 25.0% quarter-over-quarter from -$109.9 million in Q4 2025.
Stevanato Group S.p.A (STVN) Cash from Investing Activities (2020 - 2026) Analysis & Trends
Stevanato Group S.p.A (STVN) has 7 years of Cash from Investing Activities data on file, last reported at -$82.4 million in Q1 2026.
- Cash from Investing Activities for Q1 2026 came in at -$82.4 million, down 10.81% year-over-year; the trailing twelve-month figure through Mar 2026 was -$316.2 million (down 5.85% YoY), and the FY2025 annual result was -$317.7 million, up 4.17% from the prior year.
- Cash from Investing Activities improved to -$82.4 million in Q1 2026 per STVN's latest filing, from -$109.9 million in the prior quarter.
- Over five years, Cash from Investing Activities peaked at -$43.6 million in Q3 2022 and troughed at -$143.9 million in Q3 2023.
- A 5-year average of -$85.5 million and a median of -$81.3 million in 2022 frame the typical range for Cash from Investing Activities.
- The sharpest annual moves came in 2023 and 2024: Cash from Investing Activities sank 230.4% in 2023, then soared 63.7% in 2024.
- A 5-year view of Cash from Investing Activities shows it stood at -$70.3 million in 2022, then sank by 41.27% to -$99.3 million in 2023, then climbed by 2.08% to -$97.2 million in 2024, then retreated by 13.0% to -$109.9 million in 2025, then rose by 25.0% to -$82.4 million in 2026.
- Business Quant data shows STVN's Cash from Investing Activities at -$82.4 million in Q1 2026, -$109.9 million in Q4 2025, and -$56.3 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing (Qtr) |
|---|---|---|---|---|---|
| 1 | Intuitive Surgical | 148.09 Bn | 143.69 Bn | 1.83 Bn | -914.50 Mn |
| 2 | Becton Dickinson | 41.00 Bn | 39.99 Bn | 2.15 Bn | -139.00 Mn |
| 3 | Medline | 30.38 Bn | 36.22 Bn | 1.84 Bn | -96.00 Mn |
| 4 | Resmed | 28.22 Bn | 26.56 Bn | 890.98 Mn | -58.03 Mn |
| 5 | West Pharmaceutical Services | 23.72 Bn | 23.19 Bn | 296.40 Mn | -42.70 Mn |
| 6 | Solventum | 13.33 Bn | 13.33 Bn | 1.10 Bn | -77.00 Mn |
| 7 | Cooper Companies | 13.12 Bn | 12.99 Bn | 735.40 Mn | -90.00 Mn |
| 8 | Align Technology | 12.86 Bn | 11.80 Bn | 736.59 Mn | -131.58 Mn |
| 9 | Baxter International | 10.51 Bn | 8.47 Bn | 891.00 Mn | -133.00 Mn |
| 10 | Stevanato Group S.p.A | 433.37 Mn | 290.42 Mn | 88.01 Mn | -82.42 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -82.42 Mn |
| Mar 31, 2026 | -82.42 Mn |
| Dec 31, 2025 | -109.89 Mn |
| Dec 31, 2025 | -109.89 Mn |
| Sep 30, 2025 | -56.34 Mn |
| Sep 30, 2025 | -56.34 Mn |
| Jun 30, 2025 | -67.53 Mn |
| Jun 30, 2025 | -67.53 Mn |
| Mar 31, 2025 | -74.38 Mn |
| Mar 31, 2025 | -74.38 Mn |
| Dec 31, 2024 | -97.24 Mn |
| Dec 31, 2024 | -97.24 Mn |
| Sep 30, 2024 | -52.24 Mn |
| Sep 30, 2024 | -52.24 Mn |
| Jun 30, 2024 | -74.84 Mn |
| Jun 30, 2024 | -74.84 Mn |
| Mar 31, 2024 | -110.93 Mn |
| Mar 31, 2024 | -110.93 Mn |
| Dec 31, 2023 | -99.31 Mn |
| Dec 31, 2023 | -99.31 Mn |